{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:13:53Z","timestamp":1790835233111,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3) cause respiratory tract illness in children and the elderly. No licensed vaccines are available.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this phase 1, randomized, dose-ranging, first-in-human study, the safety, reactogenicity, and humoral immunogenicity of an investigational mRNA-based hMPV and PIV3 combination vaccine, mRNA-1653, were evaluated in healthy adults aged 18\u201349 years. Sentinel participants (n\u2009=\u200920) received 2 doses of mRNA-1653 (25, 75, 150, or 300\u2005\u03bcg) in the dose escalation phase, and participants (n\u2009=\u2009104) received 2 doses of mRNA-1653 (75, 150, or 300\u2005\u03bcg) or placebo in the dose selection phase; injections were 28 days apart.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most common solicited reactogenicity events were injection site pain, headache, fatigue, and myalgia, the majority of which were grade 1 or 2. A single mRNA-1653 dose increased neutralization titers against hMPV and PIV3 1 month after vaccination compared with baseline. No notable increases in neutralizing antibody titers were observed with escalating dose levels after mRNA-1653, although no statistical inferences were made; a second mRNA-1653 dose had little observable impact on antibody titers. Neutralizing titers through 1 year remained above baseline for hMPV and returned to baseline for PIV3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>mRNA-1653 was well tolerated, with an acceptable safety profile and increased hMPV and PIV3 neutralization titers in healthy adults.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac206","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T14:32:43Z","timestamp":1651761163000},"source":"Crossref","is-referenced-by-count":82,"title":["Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults"],"prefix":"10.1093","volume":"9","author":[{"given":"Allison","family":"August","sequence":"first","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A","family":"Shaw","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lee","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Knightly","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Kalidindia","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Chu","sequence":"additional","affiliation":[{"name":"Benchmark Research , Austin, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J","family":"Essink","sequence":"additional","affiliation":[{"name":"Meridian Clinical Research , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Seger","sequence":"additional","affiliation":[{"name":"Benchmark Research , Fort Worth, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Zaks","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Panther","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,1]]},"reference":[{"key":"2022073009491420000_ofac206-B1","article-title":"Human metapneumovirus (HMPV) clinical features","author":"Centers for Disease Control and Prevention"},{"key":"2022073009491420000_ofac206-B2","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3201\/eid1004.030393","article-title":"Antigenic and genetic variability of human metapneumoviruses","volume":"10","author":"van den Hoogen","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"2022073009491420000_ofac206-B3","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1099\/jgv.0.000959","article-title":"ICTV virus taxonomy profile: pneumoviridae","volume":"98","author":"Rima","year":"2017","journal-title":"J Gen Virol"},{"key":"2022073009491420000_ofac206-B4","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2214-109X(20)30393-4","article-title":"Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study","volume":"9","author":"Wang","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2022073009491420000_ofac206-B5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1204630","article-title":"Burden of human metapneumovirus infection in young children","volume":"368","author":"Edwards","year":"2013","journal-title":"N Engl J Med"},{"key":"2022073009491420000_ofac206-B6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcv.2011.10.010","article-title":"An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility for the elderly in Oregon","volume":"53","author":"Liao","year":"2012","journal-title":"J Clin Virol"},{"key":"2022073009491420000_ofac206-B7","first-page":"909","article-title":"Outbreaks of human metapneumovirus in two skilled nursing facilities \u2013 West Virginia and Idaho, 2011\u20132012","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022073009491420000_ofac206-B8","article-title":"Clinical overview of human parainfluenza viruses (HPIVs). Updated 31 October 2019","author":"Centers for Disease Control and Prevention"},{"key":"2022073009491420000_ofac206-B9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/513975","article-title":"Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children &lt;5 years old","volume":"175","author":"Reed","year":"1996","journal-title":"J Infect Dis"},{"key":"2022073009491420000_ofac206-B10","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1542\/peds.113.6.1758","article-title":"Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children","volume":"113","author":"Iwane","year":"2004","journal-title":"Pediatrics"},{"key":"2022073009491420000_ofac206-B11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jpeds.2008.11.034","article-title":"Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization","volume":"154","author":"Weinberg","year":"2009","journal-title":"J Pediatr"},{"key":"2022073009491420000_ofac206-B12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa025472","article-title":"Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children","volume":"350","author":"Williams","year":"2004","journal-title":"N Engl J Med"},{"key":"2022073009491420000_ofac206-B13","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1001\/archinte.168.22.2489","article-title":"Human metapneumovirus infections in adults: another piece of the puzzle","volume":"168","author":"Walsh","year":"2008","journal-title":"Arch Intern Med"},{"key":"2022073009491420000_ofac206-B14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1086\/367901","article-title":"Human metapneumovirus infections in young and elderly adults","volume":"187","author":"Falsey","year":"2003","journal-title":"J Infect Dis"},{"key":"2022073009491420000_ofac206-B15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/0003-4819-144-5-200603070-00010","article-title":"Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients","volume":"144","author":"Englund","year":"2006","journal-title":"Ann Intern Med"},{"key":"2022073009491420000_ofac206-B16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jinf.2005.11.010","article-title":"Human metapneumovirus and exacerbations of chronic obstructive pulmonary disease","volume":"53","author":"Martinello","year":"2006","journal-title":"J Infect"},{"key":"2022073009491420000_ofac206-B17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2334-13-28","article-title":"Epidemiology and clinical presentation of the four human parainfluenza virus types","volume":"13","author":"Liu","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2022073009491420000_ofac206-B18","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/bmt.2010.347","article-title":"A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality","volume":"46","author":"Hodson","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"2022073009491420000_ofac206-B19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2016.05.035","article-title":"Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review","volume":"379","author":"Shah","year":"2016","journal-title":"Cancer Lett"},{"key":"2022073009491420000_ofac206-B20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1099\/vir.0.000083","article-title":"Recent vaccine development for human metapneumovirus","volume":"96","author":"Ren","year":"2015","journal-title":"J Gen Virol"},{"key":"2022073009491420000_ofac206-B21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2013 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2022073009491420000_ofac206-B22","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"2022073009491420000_ofac206-B23","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2013 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"2022073009491420000_ofac206-B24","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"2022073009491420000_ofac206-B25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"2022073009491420000_ofac206-B26","article-title":"Updated 1 April 2021","volume-title":"Moderna COVID-19 vaccine","author":"Food and Drug Administration"},{"key":"2022073009491420000_ofac206-B27","volume-title":"EMA recommends COVID-19 vaccine Moderna for authorisation in the EU","author":"European Medicines Agency"},{"key":"2022073009491420000_ofac206-B28","volume-title":"Moderna COVID-19 vaccine: authorized with conditions","author":"Government of Canada"},{"key":"2022073009491420000_ofac206-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"2022073009491420000_ofac206-B30","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci Adv"},{"key":"2022073009491420000_ofac206-B31","doi-asserted-by":"crossref","first-page":"100746","DOI":"10.1016\/j.eclinm.2021.100746","article-title":"mRNA vaccines: a matter of delivery","volume":"32","author":"Cao","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2022073009491420000_ofac206-B32","volume-title":"Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials","author":"US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research"},{"key":"2022073009491420000_ofac206-B33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1743-422X-2-84","article-title":"Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis","volume":"2","author":"Zielinska","year":"2005","journal-title":"Virol J"},{"key":"2022073009491420000_ofac206-B34","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/89098","article-title":"A newly discovered human pneumovirus isolated from young children with respiratory tract disease","volume":"7","author":"van den Hoogen","year":"2001","journal-title":"Nat Med"},{"key":"2022073009491420000_ofac206-B35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1055\/s-0036-1584798","article-title":"Parainfluenza virus infection","volume":"37","author":"Branche","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"2022073009491420000_ofac206-B36","doi-asserted-by":"crossref","first-page":"e1005859","DOI":"10.1371\/journal.ppat.1005859","article-title":"Engineering, structure and immunogenicity of the human metapneumovirus F protein in the postfusion conformation","volume":"12","author":"M\u00e1s","year":"2016","journal-title":"PLoS Pathog"},{"key":"2022073009491420000_ofac206-B37","doi-asserted-by":"crossref","first-page":"12265","DOI":"10.1073\/pnas.1811980115","article-title":"Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4","volume":"115","author":"Stewart-Jones","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022073009491420000_ofac206-B38","doi-asserted-by":"crossref","first-page":"e2106196118","DOI":"10.1073\/pnas.2106196118","article-title":"Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses","volume":"118","author":"Stewart-Jones","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022073009491420000_ofac206-B39","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","article-title":"The value of childhood combination vaccines: from beliefs to evidence","volume":"11","author":"Maman","year":"2015","journal-title":"Hum Vaccin Immunother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac206\/43516196\/ofac206.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac206\/45028905\/ofac206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/7\/ofac206\/45028905\/ofac206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T09:50:26Z","timestamp":1659174626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac206\/6576476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac206","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,5,1]]},"article-number":"ofac206"}}